TP-05: An investigational therapeutic for the prevention of Lyme disease

What is TP-05?

TP-05 is an oral, systemic formulation of lotilaner in development for the prevention of Lyme disease.1

Currently, there is no FDA-approved pharmacological option for preventing Lyme disease.1

TP-05 is1:

Reference:

1. Tarsus Pharmaceuticals, Inc. initiates phase 1 Callisto trial of TP-05, a novel, oral, non-vaccine therapeutic for the prevention of Lyme disease. Tarsus Pharmaceuticals, Inc. Press release. June 16, 2021.

Learn more about our efforts to prevent Lyme disease.

Contact Tarsus

Please reach out to us using the form below.

General Information
Investor Relations
Opt in to be the first to receive the latest Tarsus news
Contact Tarsus

Thank you for getting in touch! Someone from our team will respond shortly.